• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

细胞外囊泡在非霍奇金淋巴瘤治疗干预中的多方面作用

The multifaceted roles of extracellular vesicles for therapeutic intervention with non-Hodgkin lymphoma.

作者信息

Lee Arthur A, Godwin Andrew K, Abdelhakim Haitham

机构信息

Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA.

Bioengineering Program, The University of Kansas, Lawrence, KS 64111, USA.

出版信息

Extracell Vesicles Circ Nucl Acids. 2024 Jun;5(2):329-343. doi: 10.20517/evcna.2024.07. Epub 2024 Jun 25.

DOI:10.20517/evcna.2024.07
PMID:39639879
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11618822/
Abstract

Extracellular vesicles (EVs) contribute to the development of cancer in various ways. Non-Hodgkin lymphoma (NHL) is a cancer of mature lymphocytes and the most common hematological malignancy globally. The most common form of NHL, diffuse large B-cell lymphoma (DLBCL), is primarily treated with chemotherapy, autologous stem cell transplantation (ASCT), and/or chimeric antigen receptor T-cell (CAR-T) therapy. With NHL disease progression and its treatment, extracellular vesicles play remarkable roles in influencing outcomes. This finding can be utilized for therapeutic intervention to improve patient outcomes for NHL. This review focuses on the multifaceted roles of EVs with NHL and its potential for guiding patient care.

摘要

细胞外囊泡（EVs）以多种方式促进癌症的发展。非霍奇金淋巴瘤（NHL）是一种成熟淋巴细胞癌症，也是全球最常见的血液系统恶性肿瘤。NHL最常见的形式是弥漫性大B细胞淋巴瘤（DLBCL），主要通过化疗、自体干细胞移植（ASCT）和/或嵌合抗原受体T细胞（CAR-T）疗法进行治疗。随着NHL疾病的进展及其治疗，细胞外囊泡在影响治疗结果方面发挥着显著作用。这一发现可用于治疗干预，以改善NHL患者的治疗结果。本综述重点关注细胞外囊泡在NHL中的多方面作用及其指导患者护理的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e6/11648404/98307a77cf4c/evcna-5-2-329.fig.3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e6/11648404/bbeaa9cdc349/evcna-5-2-329.fig.1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e6/11648404/9341c6b4da59/evcna-5-2-329.fig.2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e6/11648404/98307a77cf4c/evcna-5-2-329.fig.3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e6/11648404/bbeaa9cdc349/evcna-5-2-329.fig.1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e6/11648404/9341c6b4da59/evcna-5-2-329.fig.2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e6/11648404/98307a77cf4c/evcna-5-2-329.fig.3.jpg

相似文献

1
The multifaceted roles of extracellular vesicles for therapeutic intervention with non-Hodgkin lymphoma.细胞外囊泡在非霍奇金淋巴瘤治疗干预中的多方面作用
Extracell Vesicles Circ Nucl Acids. 2024 Jun;5(2):329-343. doi: 10.20517/evcna.2024.07. Epub 2024 Jun 25.
2
Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant.自体造血干细胞移植治疗复发/难治性非霍奇金淋巴瘤患儿、青少年及青年患者的特征和结局。
BMC Cancer. 2023 Dec 20;23(1):1258. doi: 10.1186/s12885-023-11712-6.
3
Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.难治性/复发性B细胞非霍奇金淋巴瘤患者在自体干细胞移植加嵌合抗原受体T细胞治疗前，卡莫司汀、依托泊苷、阿糖胞苷和美法仑（BEAM）方案与卡莫司汀、依托泊苷、阿糖胞苷、美法仑和氟达拉滨（BEAMF）方案的预后差异。
Cytotherapy. 2024 May;26(5):456-465. doi: 10.1016/j.jcyt.2024.01.012. Epub 2024 Feb 19.
4
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
5
Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma.嵌合抗原受体 T 细胞治疗后程序性细胞死亡受体 1 抑制剂维持治疗复发/难治性 B 细胞非霍奇金淋巴瘤的疗效。
Cell Oncol (Dordr). 2024 Aug;47(4):1425-1440. doi: 10.1007/s13402-024-00940-y. Epub 2024 Apr 2.
6
CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.自体移植后复发/难治性侵袭性 B 细胞淋巴瘤患者的 CD19/CD22 嵌合抗原受体 T 细胞鸡尾酒疗法。
Transplant Cell Ther. 2021 Nov;27(11):910.e1-910.e11. doi: 10.1016/j.jtct.2021.08.012. Epub 2021 Aug 20.
7
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.利妥昔单抗：用于非霍奇金淋巴瘤和慢性淋巴细胞白血病的综述
Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005.
8
Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.嵌合抗原受体T细胞疗法治疗B细胞非霍奇金淋巴瘤的进展
Biomark Res. 2021 Jul 13;9(1):58. doi: 10.1186/s40364-021-00309-5.
9
Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: A meta-analysis.第二代嵌合抗原受体T细胞疗法治疗弥漫性大B细胞淋巴瘤的疗效与安全性：一项荟萃分析。
Mol Clin Oncol. 2020 Oct;13(4):33. doi: 10.3892/mco.2020.2103. Epub 2020 Jul 29.
10
Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.含噻替哌的预处理方案用于自体干细胞移植的长期结果。
Transplant Cell Ther. 2023 Aug;29(8):505.e1-505.e8. doi: 10.1016/j.jtct.2023.04.022. Epub 2023 May 7.

引用本文的文献

1
Circulating Biomarker Panorama in HIV-Associated Lymphoma: A Bridge from Early Risk Warning to Prognostic Stratification.HIV相关淋巴瘤中的循环生物标志物全景：从早期风险预警到预后分层的桥梁
Biomolecules. 2025 Jul 11;15(7):993. doi: 10.3390/biom15070993.
2
CAR-T cell therapy in brain malignancies: obstacles in the face of cellular trafficking and persistence.嵌合抗原受体T细胞疗法在脑恶性肿瘤中的应用：细胞转运与存活面临的障碍
Front Immunol. 2025 Jun 19;16:1596499. doi: 10.3389/fimmu.2025.1596499. eCollection 2025.

本文引用的文献

1
Extracellular Vesicles as Liquid Biopsy Biomarkers across the Cancer Journey: From Early Detection to Recurrence.细胞外囊泡作为贯穿癌症诊治全过程的液体活检生物标志物：从早期检测到复发。
Clin Chem. 2024 Jan 4;70(1):206-219. doi: 10.1093/clinchem/hvad176.
2
Tissue-derived extracellular vesicles in cancer progression: mechanisms, roles, and potential applications.组织来源的细胞外囊泡在癌症进展中的作用机制、角色和潜在应用。
Cancer Metastasis Rev. 2024 Jun;43(2):575-595. doi: 10.1007/s10555-023-10147-6. Epub 2023 Oct 18.
3
B cell extracellular vesicles contain monomeric IgM that binds antigen and enters target cells.
B细胞外囊泡含有能结合抗原并进入靶细胞的单体IgM。
iScience. 2023 Aug 3;26(9):107526. doi: 10.1016/j.isci.2023.107526. eCollection 2023 Sep 15.
4
Extracellular Vesicles as Drug Transporters.细胞外囊泡作为药物转运体。
Int J Mol Sci. 2023 Jun 17;24(12):10267. doi: 10.3390/ijms241210267.
5
The epidemiological patterns of non-Hodgkin lymphoma: global estimates of disease burden, risk factors, and temporal trends.非霍奇金淋巴瘤的流行病学模式：疾病负担、风险因素及时间趋势的全球估计
Front Oncol. 2023 Jun 2;13:1059914. doi: 10.3389/fonc.2023.1059914. eCollection 2023.
6
Extracellular Vesicles and Epidermal Growth Factor Receptor Activation: Interplay of Drivers in Cancer Progression.细胞外囊泡与表皮生长因子受体激活：癌症进展中驱动因素的相互作用
Cancers (Basel). 2023 May 30;15(11):2970. doi: 10.3390/cancers15112970.
7
Extracellular Vesicles in Liquid Biopsies as Biomarkers for Solid Tumors.液体活检中的细胞外囊泡作为实体瘤的生物标志物
Cancers (Basel). 2023 Feb 18;15(4):1307. doi: 10.3390/cancers15041307.
8
Extracellular vesicles and nanoparticles: emerging complexities.细胞外囊泡和纳米颗粒：不断涌现的复杂性。
Trends Cell Biol. 2023 Aug;33(8):667-681. doi: 10.1016/j.tcb.2023.01.002. Epub 2023 Feb 1.
9
Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells.外泌体表达 CD19 抗原可提高 CD19 靶向 CAR-T 细胞的扩增和疗效。
Int J Nanomedicine. 2023 Jan 5;18:49-63. doi: 10.2147/IJN.S390720. eCollection 2023.
10
CAR-tropic extracellular vesicles carry tumor-associated antigens and modulate CAR T cell functionality.CAR 靶向细胞外囊泡携带肿瘤相关抗原并调节 CAR T 细胞功能。
Sci Rep. 2023 Jan 10;13(1):463. doi: 10.1038/s41598-023-27604-5.